| Literature DB >> 27013372 |
Amareshwar Chiruvella1, David A Kooby2.
Abstract
Pancreatic neuroendocrine tumors (pancNETs) are rare neoplasms that comprise 2% to 4% of all clinically detected pancreatic tumors. They are usually indolent, and their malignant potential is often underestimated. The management of this disease poses a challenge because of the heterogeneous clinical presentation and varying degree of aggressiveness. Treatment decisions for this clinical entity are still patient- and/or physician-specific. Optimal clinical management of pancNETs requires a multidisciplinary approach. The only potentially curative treatment option, especially in the early stage disease, remains surgical resection; however, as many as 75% of patients present with advanced disease (nodal and/or distant metastases).Entities:
Keywords: Carcinoid; Gastrinoma; Hepatectomy; Insulinoma; Neuroendocrine tumor; Pancreatectomy; Pancreatic neoplasm
Mesh:
Year: 2016 PMID: 27013372 DOI: 10.1016/j.soc.2015.12.002
Source DB: PubMed Journal: Surg Oncol Clin N Am ISSN: 1055-3207 Impact factor: 3.495